Navigation Links
InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
Date:11/6/2008

- Third quarter net loss narrows on higher revenue due to Roche milestone -

BRISBANE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced results from operations for the third quarter and nine months ended September 30, 2008. InterMune reported a net loss for the third quarter of 2008 of $12.5 million, or $0.32 per share, compared with a net loss of $23.1 million, or $0.66 per share, in the third quarter of 2007.

Dan Welch, Chairman, Chief Executive Officer and President of InterMune said, "Third quarter and recent events have highlighted our significant progress on pirfenidone and ITMN-191. On October 16, Shionogi's Japanese NDA for pirfenidone was approved, making pirfenidone the first drug approved for idiopathic pulmonary fibrosis (IPF) in any major market in the world. We reported exceptional patient retention in our Phase 3 CAPACITY program for pirfenidone in IPF and we set the expectation for announcement of top-line results from CAPACITY in January or February of 2009. With ITMN-191, we remain committed to announcing top-line results of our triple combination study of ITMN-191 with Pegasys(R) (pegylated interferon alfa-2a) and Copegus(R) (ribavirin) during this quarter."

Results for Third Quarter 2008

InterMune reported total revenue in the third quarter of 2008 of $23.3 million, compared with total revenue of $11.4 million in the third quarter of 2007. Total revenue in the third quarter of 2008 primarily consisted of revenue from the collaboration with Roche for the development of protease inhibitors, including ITMN-191 (R7227), which totaled $15.8 million in the third quarter of 2008, compared with $0.8 million in the same quarter of 2007. Third quarter 2008 collaborati
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... -- R-Japan Co.,Ltd. obtained the license of cell processing facility ... the Ministry of Health, Labour and Welfare Kinki Bureau of ... The fact that R- Japan received the ... and Medical Devices Agency (PMDA) on May 18, 2015 two ... cell manufacturing service to medical institutions. As of November 25, ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)...  NASA astronaut Kjell Lindgren , who is making ... mission to the International Space Station , will be ... EDT Tuesday, July 7. Lindgren will participate from ... Russia . The interviews will be preceded at 7:30 ... training. To schedule an interview, media must contact ...
(Date:6/30/2015)... , June 30, 2015  Today, Americord Registry, one of ... Andrew Horne , a partner at Kirkland & Ellis ... Logo - http://photos.prnewswire.com/prnh/20150630/226958LOGO   "We ... Advisory Board," says Martin Smithmyer , CEO of Americord. ... legal career that will assist Americord,s growth and vision." ...
Breaking Biology Technology:R-Japan Obtained Autologous Stem Cell Manufacturing License from the Ministry of Health, Labour and Welfare 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2Americord Registry Announces Andrew Horne as Advisory Board Member 2
... for Business Intelligence (CBI) announced today that the company will ... the relief efforts in Japan following a devastating earthquake and ... the organization matched employee donations. "I am so ... to help a nation in a desperate time of need," ...
... Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) ... (Barbados) SRL (VIB), received a commitment in principle to ... U.S., Canada and Mexico.  Terms of the license will ... agreement.  Earlier today Meda announced that it reached a ...
... and engineers, as well as students working in ... curve when developing common MEMS fabrication processes. A ... Springer promises to be an important game-changing asset ... and Processes Handbook is an exhaustive design reference ...
Cached Biology Technology:The Center for Business Intelligence Donates to the American Red Cross, Matching Employee Contributions for Disaster Relief in Japan 2Meda to License Elidel to Valeant Pharmaceuticals 2MEMS Materials and Processes Handbook -- a comprehensive, practical resource 2
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - handyem ... centralized around the incorporation of handyem,s HPC-150 portable ... laboratory, the Mo-POD™. This unprecedented model of mobile ... Conference at the Pennsylvania ... June 15 th to 18 th ...
(Date:6/15/2015)... June 16, 2015 According to ... by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, ... 2020" published by MarketsandMarkets, The Natural Language Processing Market ... CAGR of 18.4% for the forecast period 2015-2020. ... 46 F igures spread   through 155 P ...
(Date:6/11/2015)... Daon, a global leader in mobile ... Mobile Authentication Platform v4.0 has been FIDO Certified™.  ... industry consortium launched in 2013 to revolutionize online ... In order to receive certification, a company,s products ... tests that measure compliance and ensure interoperability among ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2
... the gene that sets off a sequence of events ... can lead to high blood pressure. The disease process ... of blockages that can cause heart attacks, strokes and ... led by Ohio State University researchers might lead to ...
... treat iron poisoning can significantly boost the bodys own ... researchers at the University of Alabama at Birmingham (UAB). ... is designed to reduce iron overload, into injured mouse ... blood vessels, which in turn kicked off bone re-growth ...
... has shown promising results in fighting a severe genetic disorder ... genetic knowledge have transformed our understanding of disease in recent ... wide variety of conditions. However, so far, very few cures ... Now a UK study led by researchers at Cardiff ...
Cached Biology News:High blood pressure in older adults traced to gene's effects in blood vessels 2High blood pressure in older adults traced to gene's effects in blood vessels 3New treatment boosts bone healing and regrowth 2Genetic breakthrough offers promise in tackling kidney tumors 2
AMAP Multi Site-directed Mutagenesis Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: dry ice...
Umbilical cord blood eosinophils, For immunohistochemistry (IHC)...
Slide Chambers are convenient for performing pre-hybridization incubations and post-hybridization washes with tissue sections mounted on standard glass microscope slides. Each chamber holds up to 5 s...
Human peripheral blood PBMCs, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood PBMC and T Cells...
Biology Products: